As domestic pharmaceutical manufacturers' GMP (Good Manufacturing Practice) violations occur one after another, the National Assembly and the MFDS are struggling to prevent recurrence by strengthening regulations.

The National Assembly is considering reinforcing the administrative disposition of pharmaceutical companies violating GMP through the legalization of the Ordinance of the Prime Minister and the Pharmaceutical Affairs Act of the GMP regulation, which is operated by public notice, and the MFDS is trying to organize a special planning inspection team regularly and operate it on a regular basis. On the 4th, the National Assembly and the MFDS are discussing to resolve the problem of GMP violation